In the present study, we demonstrate that a hybrid vaccine developed using influenza VLP vaccine incorporated with GPI-RBD-GM-CSF fusion protein and GPI-IL-12 protected mice from influenza virus challenge and also induced a robust, durable antibody response in BALB/c mice as well as decreased viral load and less weight loss when challenged with mouse-adapted SARS-CoV-2. Here, CSF2 is linked to influenza.